Pulmonx Q4 2025 Results: A Litmus Test for New Leadership

Pulmonx Corp US7458481014

Investors in Pulmonx Corp are setting their sights on the latter part of February. The medical technology firm is poised to release its financial results for the final quarter of 2025. Following a year marked by strategic shifts, the central question is whether the company has successfully met its ambitious annual targets.

Beyond the raw financial metrics, the market will be scrutinizing the performance of a recently installed leadership team. In late 2025, Glen French reassumed the role of Chief Executive Officer, while Derrick Sung joined the executive ranks as Chief Operating and Financial Officer. The imminent quarterly report represents the first set of numbers for which this new duo bears full responsibility. Their effectiveness in navigating the competitive landscape will be a key focus.

The broader pulmonology market continues to evolve. Advances in diagnostic tools for severe lung diseases are driving demand for innovative treatment solutions. This trend benefits Pulmonx, as its flagship Zephyr Valve system is already approved for the treatment of severe emphysemain more than 25 countries worldwide.

Revenue Targets and Regional Performance

Market expectations are guided by the company's most recent forecast, updated in November. For the full 2025 fiscal year, management has projected revenue in the range of $89 to $90 million. The gross margin is anticipated to remain stable at approximately 73%.

A particular point of interest will be the breakdown of sales by geography. An intriguing dynamic emerged in the third quarter of 2025: while global revenue reached $21.5 million, the international business segment expanded at a notably faster pace than the core U.S. market. Shareholders will be watching closely to see if this divergence became more pronounced by year's end.

The detailed quarterly figures are scheduled for release around February 18th or between February 24th and 25th, 2026. This disclosure will provide critical insight into the operational execution of the refreshed leadership team and the company's trajectory as it heads into a new fiscal period.